Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

manilatimes.net · 2026-09-01

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Chris Murphy, chief financial officer, is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, Sept. 15, 2026. The presentation is scheduled to begin at 3:30pm ET.

TickrTrends take: Anaptys' participation in the H.C. Wainwright conference represents an opportunity for the company to present its pipeline and business strategy to investors, which becomes particularly relevant given that TickrTrends is currently awaiting a full valuation assessment for the Healthcare sector company. For valuation-focused readers, such conference presentations typically provide updated financial guidance, clinical development timelines, or partnership announcements that can materially influence fair value estimates. Observers should monitor whether ANAB discloses information that could accelerate or modify the timeline for reaching a completed valuation.

Read the full story at manilatimes.net →